Baxter calls spin-off company Edwards Lifesciences:
This article was originally published in Clinica
Executive Summary
Baxter is to call the newly formed cardiovascular company - expected to be spun off from Baxter in the first half of 2000 - Edwards Lifesciences (see Clinica No 867, p 1). Baxter's vice-president, Michael Mussallem, will be the company's CEO and chairman. The company is to be named after Miles Edwards, the man who co-invented the first commercially available artificial heart valve. Edwards, which will have annual sales of nearly $1 billion, will be based in Irvine, California and will employ around 5,000 people worldwide.